'Therapy speak' is everywhere, but it may make us less empathetic
NPR's Andrew Limbong speaks with culture writer Rebecca Fishbein about her article for Bustle on how "therapy speak" may be making us less empathetic.
Health & Safety
You're less likely to get long COVID after a second infection than a first
The chances of developing lingering symptoms after COVID appears to fall sharply from the first to the second time someone gets sick, new research finds. The risk is still significant.
Syphilis cases spike in North Carolina
Syphilis cases are on the rise in North Carolina. The problem has become especially acute for women and babies.
Abortion providers wait for the Supreme Court to weigh in on mifepristone
The Supreme Court will weigh in on whether doctors can still provide patients with mifepristone across the country. Abortion providers share how they're navigating this uncertainty with patients.
The pharmaceutical industry urges courts to preserve access to abortion pill
As the debate over mifepristone makes its way to the Supreme Court, the pharmaceutical industry has raised concerns that ruling against the FDA could chill the development of new drugs.
Here's what really happened during the abortion drug's approval 23 years ago
A Texas judge ruled that the Food and Drug Administration wrongly approved mifepristone in 2000 and accused it of doing a rush job. Here's what really went down.
U.S. appeals court preserves partial access to abortion pill, but with tighter rules
The Biden administration had asked the higher court to stay a decision from a Texas judge while the appeal plays out.
Share your story: Have you used medication for abortion or miscarriage care?
NPR would like to hear from you. With the future of some abortion pills in jeopardy, tell us about your experience using medication to end a pregnancy or treat a miscarriage.
U.S. appeals court preserves mifepristone approval, but with limitations
A U.S. appeals court ruling ratchets approval of the abortion pill mifepristone from 10 weeks of pregnancy down to seven weeks and says that — for now — the drug can no longer be sent in the mail.
Medicare tests a solution to soaring hospice costs: Let private insurers run it
The end-of-life benefit costs billions a year. A new approach aims to eliminate waste and weed out bad actors, while making the care more inviting to those who most need it.